Receptos, Inc. IPO Info
Company Name: Receptos, Inc.
Stock Symbol: RCPT
Exchange: NASDAQ
Status: Priced
IPO Date: 5/9/2013
IPO Price:
14.00 (
107.07%)
Underwriters
Credit Suisse, Leerink Swann, BMO Capital Markets, Wedbush PacGrow Life Sciences
Amount of Offering: N/A
Number of Shares Offered: 5.2 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).
SEC Filings
News Headlines
